Spots Global Cancer Trial Database for Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment
Official Title: Multicentre, Open Label, Extension Study of Treatment With Gefitinib(IRESSA™) for Patients Completing Other Gefitinib Clinical Studies Who May Benefit From Gefitinib Treatment
Study ID: NCT00683306
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to provide gefitinib treatment to patients who, on completion or closure of other gefitinib clinical studies, were either receiving placebo treatment, or are continuing on the same dose and regimen of gefitinib established in their preceding study, for as long as the patients continue to derive benefit.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Research Site, La Plata, , Argentina
Research Site, Concord, , Australia
Research Site, Graz, , Austria
Research Site, Linz, , Austria
Research Site, Wien, , Austria
Research Site, Fortaleza, , Brazil
Research Site, Porto Alegre, , Brazil
Research Site, Rio de Janeiro, , Brazil
Research Site, Sao Paulo, , Brazil
Research Site, Sao Paulo, , Brazil
Research Site, Sorocaba, , Brazil
Research Site, Plovdiv, , Bulgaria
Research Site, Sofia, , Bulgaria
Research Site, Sofia, , Bulgaria
Research Site, Sofia, , Bulgaria
Research Site, Varna, , Bulgaria
Research Site, Veliko Tarnovo, , Bulgaria
Research Site, Tallinn, , Estonia
Research Site, Tartu, , Estonia
Research Site, Budapest, , Hungary
Research Site, Deszk, , Hungary
Research Site, Mosdós, , Hungary
Research Site, Pécs, , Hungary
Research Site, Zalaegerszeg, , Hungary
Research Site, Hyderabad, , India
Research Site, Karnataka, , India
Research Site, Kolkata, , India
Research Site, Mumbai, , India
Research Site, New Delhi, , India
Research Site, Pune, , India
Research Site, Vellore, , India
Research Site, Daugavpils, , Latvia
Research Site, Riga, , Latvia
Research Site, Kuala Lumpur, , Malaysia
Research Site, Nilai, , Malaysia
Research Site, Penang, , Malaysia
Research Site, Penang, , Malaysia
Research Site, Penang, , Malaysia
Research Site, Durango, , Mexico
Research Site, Mexico Distrito Federal, , Mexico
Research Site, Monterrey, , Mexico
Research Site, Torreon, , Mexico
Research Site, Manila, , Philippines
Research Site, Pasig, , Philippines
Research Site, Quezon City, , Philippines
Research Site, Quezon City, , Philippines
Research Site, Bucharest, , Romania
Research Site, Iasi, , Romania
Research Site, Moscow, , Russian Federation
Research Site, Moscow, , Russian Federation
Research Site, Singapore, , Singapore
Research Site, Johannesburg, , South Africa
Research Site, Kaohsiung, , Taiwan
Research Site, Taichung, , Taiwan
Research Site, Tainan, , Taiwan
Research Site, Taipei, , Taiwan
Research Site, Taipei, , Taiwan
Research Site, Taipei, , Taiwan
Research Site, Taipei, , Taiwan
Research Site, Tao-Yuan, , Taiwan
Research Site, Bangkok, , Thailand
Research Site, Chiang Mai, , Thailand
Research Site, Ankara, , Turkey
Research Site, Istanbul, , Turkey
Research Site, İstanbul, , Turkey
Contact Details
Name: Yuri Rukazenkov
Affiliation: AstraZeneca
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
